Analysis of Disparate Health Technology Assessment Landscape Transformed With Generative AI Tools

Enhanced HTA Vision Offering from Trinity Life Sciences Provides Efficiencies with a Layer of Expert Insights

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, today announces an enhancement to its HTA Vision offering that swiftly extracts relevant information from health technology assessments (HTAs) and Trinity expert analyses, streamlining the information-gathering process within any therapeutic area or drug class. By not only locating but also summarizing key information with generative AI (GenAI), HTA Vision transforms complex documents into clear, comprehensive overviews.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250311351638/en/

Monica Martin de Bustamante is Senior Partner and Head of Advisory at Trinity Life Sciences. (Photo: Business Wire)

HTA outcomes are lengthy, complex documents that need to be quickly digested and interpreted by Global Market Access leaders in life sciences so that they can apply the learnings to day-to-day decision-making. Expert knowledge of countries, agencies, therapeutic areas and lifecycle stage are essential to provide the context necessary to arrive at actionable recommendations for a particular brand.

“Especially in the EU, market standards and complexities are increasing, which is making the environment more challenging for pharma,” explained Monica Martin de Bustamante, Senior Partner and Head of Advisory at Trinity Life Sciences. “Combining artificial intelligence with human expertise streamlines and simplifies payer decision analysis without losing the tailored interpretations and deep insights from experts on how health authorities are evaluating products.”

“Strategic decisions for clinical development and evidence generation are made by life sciences leaders on a daily basis and need to be informed by the latest market intelligence,” added Max Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access & Pricing practice. “Trinity HTA Vision allows users to position themselves for success in a global payer landscape that can be fickle and demanding—the addition of GenAI provides users with insights on HTA drivers at their fingertips.”

Trinity HTA Vision

Trinity HTA Vision offers custom solutions to provide timely, strategic market access insights and impactful interpretation of payer decisions globally. Offerings include a cloud-based HTA dashboard with GenAI capabilities, flash alerts, HTA decision digests and readouts of key events. HTA Vision provides precise insights curated by experts with deep life sciences commercialization, global HTA and access knowledge through flexible, scalable deliverables that are customized for each client’s needs and objectives.

Virtual Demo: HTA Vision with GenAI

A virtual demo on March 13^th, HTA Vision with GenAI, will feature Trinity value, access and pricing experts Max Hunt and Andreia Ribeiro demonstrating Trinity HTA Vision’s GenAI capabilities and discussing how the cutting-edge technology meets expert analysis.

Life sciences executives are welcome to register for the virtual demo here.

About Trinity Life Sciences

With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits. To learn more about how Trinity is elevating the industry and driving evidence to action, visit TrinityLifeSciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250311351638/en/